Evidence from both animal and clinical studies suggests that hyperglycemia may be a source of additional injury to renal grafts, possibly through its effects on several molecular pathways. 19 Although the mortality benefit of tight glucose control in the intensive care unit is debated, studies in the critical care setting have demonstrated that tight glucose control is renoprotective in critically ill patients. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Despite this evidence, hyperglycemia in deceased organ donors has been largely ignored until recently. Blasi-Ibanez et al 33 demonstrated that poor glucose control in donors between declaration of brain death and organ recovery was not in line with accepted critical care standards. Furthermore, higher mean glucose concentration and greater variability in glucose concentrations were associated with worse terminal renal function in the donors. 33 In response to these results, the local organ procurement organization (OPO), California Transplant Donor Network (CTDN), implemented a quality improvement project (QIP) and modified its glycemic protocol for deceased donors to reflect standard critical care practices as detailed in the supplemental material.
The primary goal of the current study was to determine whether the QIP implementation across 80 hospitals in region 5 by CTDN resulted in improved glucose homeostasis in deceased organ donors. Given that the study by Blasi-Ibanez et al showed donor glucose control to be highly predictive of terminal renal function, one of the most important predictors of delayed graft function in kidney recipients, the secondary goal of the study is to increase the power of the original study by Blasi-Ibanez et al and assess the relationship between donor glucose control and early renal graft function in matched kidney recipients as determined by rates of delayed graft function.
Methods
Approval for this study from the Committee on Human Research at the University of California San Francisco was not required because deceased donors are not considered human subjects under federal law. CTDN developed a new insulin protocol, which was transitioned into the donor management protocols for its donation service area during a 2-month period and fully implemented by January 2009. Deceased organ donors were identified through the "CTDN" database during the period of January 2009 through August 2010. Pediatric donors (age < 18 years), DCD donors, and donors who had been enrolled in an ongoing prospective randomized study were excluded. Figure  1 summarizes the numbers in the cohorts; 241 deceased organ donors were identified after full QIP implementation and enrolled in the current study ("post-QIP donor cohort"). The 2005-2006 cohort of 458 donors, reported originally in the study by Blasi-Ibanez et al before implementation of the QIP, was used as a historic control and was designated the "pre-QIP donor cohort." No other changes in deceased donor management occurred during the time period spanned by these 2 donor cohorts. All clinical data were prospectively collected as part of the clinical care of deceased organ donor and electronically stored (iTransplant, Transplant Connect). Pertinent data elements for this study were collected as previously described. 33 A total of 543 deceased donors from both cohorts were matched with their respective kidney recipients for a total of 1036 recipients (kidneys from the remaining donors were discarded for a variety of reasons, including technical reasons and poor function). Matched kidney recipients were followed through the United Network for Organ Sharing (UNOS) database to assess for immediate graft function as defined by the presence or absence of DGF. Pediatric and combined kidney-pancreas transplant recipients were excluded from the analysis. Pertinent recipient data, including age, race, sex, and body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) were recorded. When available, operative variables including cold and warm ischemia times also were recorded. Donor blood glucose and donor terminal creatinine levels and calculated glomerular filtration rate (GFR, calculated using the Modification of Diet in Renal Disease Study equation) were used as continuous variables and were the primary donor end points. DGF was the primary recipient end point.
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Statistical Analysis
To examine the effect of the glucose management protocol modifications, we compared the pre-QIP donor cohort and the post-QIP donor cohort by using the Mann-Whitney U test for continuous variables, and a χ 2 or Fisher exact test for categorical variables. For univariate analyses, the relationship of continuous variables to terminal creatinine level or terminal GFR was analyzed by means of the Spearman rank correlation. For categorical variables, the Mann-Whitney U test or Kruskal-Wallis test was used. The relationship of continuous variables to DGF was analyzed by logistic regression. Categorical variables were analyzed by χ 2 test or Fisher exact test for 2by-2 contingency tables.
For multivariate analyses of donor renal function, all predictors were considered for entry into the models. Stepwise regression with backward elimination was used to identify the most significant predictors. Once these variables had been entered into the model, all variables that could be reasonably considered in the model were entered and tested for statistical significance regardless of whether they were significant in the univariate analysis. The distributions of both terminal creatinine level and terminal GFR were skewed, making a simple linear model ineffective. Logarithmic transformation of both creatinine level and GFR resulted in a substantially improved distribution, which led to a sufficiently robust multivariate model. Analyses were run with and without "cohort" forced into the model. Results were not appreciably different without "cohort" in the model; however, because of diffrences between groups, results are shown with "cohort" in the models. Multivariate models for DGF were developed similarly and analyzed by multiple logistic regression. Results of logistic regression for DGF were also confirmed by using a mixed-effects model with the kidney donor as a random effect.
Data are displayed as mean (SD) or as number (percentage) unless otherwise specified. Data were analyzed by using JMP 10.0 (SAS Institute) and Stata 12.1 (StataCorp). P less than .05 was considered statistically significant.
Results
Deceased Organ Donor Characteristics
Pre-QIP and post-QIP kidney donor and recipient cohorts are summarized in Figure 1 . Donor characteristics are summarized in Table 1 . The 2 donor cohorts differed significantly in ethnicity, with 10% of the pre-QIP donor cohort versus 5% of the post-QIP donor cohort being African American (P = .02). More donors in the pre-QIP cohort had experienced a cerebral vascular accident (52% vs 42%, P = .01), whereas more donors in the post-QIP cohort experienced anoxia (24% vs 13%, P < .001). The time (hours) between declaration of brain death and crossclamping of the aorta was significantly longer in the post-QIP cohort than in the pre-QIP cohort (mean [SD], 45.2 [17.8] vs 49.2 [18.8] , P = .006); however, this difference most likely does not reflect an adverse effect of the QIP and may be related to organ allocation issues.
Comparison of Glucose Homeostasis Before and After Implementation of the QIP
During the period between declaration of brain death and organ recovery, the post-QIP donor cohort had better glucose control than the pre-QIP donor cohort did ( Figure 2 ). Compared with the pre-QIP donor cohort, the post-QIP donor cohort had significantly lower mean blood glucose concentration, glucose concentration variability as determined by standard deviation, maximum glucose concentrations, and prerecovery glucose concentrations ( Table 2) .
Association of Donor Characteristics With Terminal Renal Function
Terminal renal function is summarized in Table  2 . In the univariate analysis of the post-QIP cohort ( Table 3) , older donor age was significantly related to both higher terminal creatinine level and lower terminal GFR. Higher BMI was correlated with higher terminal creatinine level (P = .005) and lower terminal GFR (P = .002). Terminal creatinine level did not differ between donors according to cause of brain death. However, GFR was higher for head trauma donors and lower for cerebral vascular accident donors (P = .002). The time between declaration of brain death and cross-clamping of the aorta was not related to terminal renal function. Donors with a history of hypertension had significantly higher terminal creatinine levels (mean [ 
Combined Cohorts
In the univariate analysis of the pre-QIP donor cohort by Blasi-Ibanez et al, 33 higher mean glucose concentration between declaration of brain death and organ recovery, maximum glucose concentration, prerecovery glucose concentration, and glucose concentration variability were all significantly associated with worsening terminal renal function.
In the univariate analysis of the post-QIP donor cohort, higher mean glucose concentrations between declaration of brain death and organ recovery were significantly associated with higher terminal creatinine level (P = .03) but were not significantly associated with terminal GFR (P = .06). However, unlike in the pre-QIP donor cohort, maximum glucose concentration, prerecovery glucose concentration, and glucose concentration variability were not associated with either terminal creatinine level or GFR (Table 3) .
In order to achieve greater power and increase the range of donor glucose concentrations, datasets were combined and the univariate analysis for donor glucose and terminal renal function was repeated. Higher mean glucose concentration between declaration of brain death and organ recovery, maximum glucose concentration, and glucose concentration variability were again all significant determinants of higher terminal creatinine level and lower terminal GFR ( Table 4) .
Results of multivariate analysis for renal function as measured by terminal creatinine level and terminal GFR are shown in Table 5 . Male sex, nonwhite ethnicity, and higher BMI were all significant determinants of worse terminal renal function. Donor history of hypertension was associated with higher terminal creatinine level and lower terminal GFR and remained highly statistically significant in the multivariate model. Mean glucose concentration correlated strongly with both higher terminal creatinine level and lower terminal GFR in the multivariate analysis. Differences between the 2 cohorts, including race, cause of death, and time from declaration of brain death to organ donation, which could be potential confounders, were addressed by including these variables in the multivariable models. When included in the multivariate analysis, these factors were not predictive of terminal renal function.
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Immediate Allograft Function in Matched Kidney Recipients
Kidney Recipient Characteristics. A total of 1036 recipients receiving a renal graft from both cohorts were followed up. The mean age was 51.4 (SD, 15.1) years; 62% of the recipients were male; 38% of recipients were white, 23% Hispanic, 20% Asian, and 15% African American; mean BMI was 26.5 (SD, 5.1).
Association of Donor and Recipient Variables
With DGF. For analysis of outcomes, pediatric recipients and patients receiving a simultaneous pancreas transplant were excluded, leaving 896 recipients who contributed data for analysis. Univariate analysis demonstrated that donor age, sex, ethnicity, BMI, history of diabetes, and history of hypertension were not associated with recipient DGF (Table 6 ). Longer cold ischemia time was significantly associated with the occurrence of DGF in the recipients (P = .004). Donor terminal renal function was highly correlated with DGF in the matched recipients. Donor glucose measurements were not significantly associated with recipient DGF. Of the recipient variables for which data were Impact of a quality improvement project on deceased organ donor management Abbreviations: BMI, body mass index; GFR, calculated glomerular filtration rate; PRA, plasma reactive antibody. a Pediatric recipients and pancreas transplants were excluded. b Odds ratios for continuous variable are for each unit increase. c Calculated as weight in kilograms divided by height in meters squared. d The word "terminal" indicates the last value before cross-clamping of aorta. available, male sex and higher BMI were significantly associated with DGF.
Impact of a quality improvement project on deceased organ donor management
Results of multivariate analysis for recipient DGF can be found in Table 7 . Separate models were developed for terminal renal function using creatinine level or GFR. Older donor age was a significant predictor of recipient DGF in the model based on creatinine level. Longer cold ischemia time remained a significant predictor of recipient DGF in the multivariate analysis. Donor terminal creatinine and terminal GFR were highly associated with DGF. Recipient male sex and higher recipient BMI were significant predictors of recipient DGF.
Discussion
The QIP implemented by "CTDN" was successful in improving glucose homeostasis in deceased organ donors. The data from this study confirmed that poor glucose control in deceased donors is an independent predictor of worsening terminal renal function. Furthermore, like previous studies, the current study showed that poor terminal renal function in the same large donor cohort is associated with DGF in corresponding kidney recipients.
From the time that a patient is declared brain dead to the time that the organs are recovered, the OPO takes over care of the donor. Therefore, donor management is standardized across hospitals in a given donation service area managed by a single OPO. A growing concern for donor management has led to the development of donor management goals (DMGs, critical care end points aimed at restoring and stabilizing the physiological functions of deceased donors). 34 Like CTDN's QIP to improve donor glucose control, these DMGs can be easily implemented given that all hospitals in a given donation service area are covered by one OPO. This arrangement makes it much easier and more feasible to educate OPO staff, implement a DMG and ensure adherence, given that it is a more centralized process. However, most evidence for DMGs is retrospective and results are conflicting regarding which individual DMGs significantly affect organ yield. [34] [35] [36] Furthermore, we lack data on how the individual DMGs affect the quality of specific donor organs and the function of grafts in corresponding recipients.
In a retrospective study of 458 deceased organ donors, Blasi-Ibanez et al 33 demonstrated poor glucose control in donors between declaration of brain death and organ recovery. Furthermore, the level of hyperglycemia in donors correlated with a decline in terminal renal function. In response to these data, CTDN implemented a QIP, modifying its glucose homeostasis protocol to reflect standard critical care practices. In this follow-up study, donors from the post-QIP cohort were managed according to the new glucose protocol.
Between declaration of brain death and organ recovery, donors from the post-QIP cohort had significantly lower glucose concentrations, showing that "CTDN's" QIP improved glucose homeostasis in deceased donors. Data from the pre-QIP donor cohort showed that higher glucose concentrations (mean, maximum, prerecovery, variability) were highly associated with worse terminal renal function. In the post-QIP donor cohort, only mean glucose concentration was significantly correlated with terminal renal function. There are several possible explanations for why we did not observe the same robust relationships in the data from the post-QIP donor cohort alone. This cohort of donors may have been underpowered to detect a correlation between donor glucose control and renal function (type 2 error). Also, glucose control in the post-QIP cohort may have been too tight, without enough spread to demonstrate a strong relationship between hyperglycemia and terminal renal function. Finally, there may be a threshold value for glucose below which glucose concentration does not have a strong impact on renal function. This threshold may be the plasma glucose concentration at which glucose appears in the urine (approximately 200 mg/dL; to convert to millimoles per liter, multiply by 0.0555). 37 When data from the 2 cohorts were combined, mean and maximum glucose concentrations as well as glucose concentration variability were again highly associated with terminal renal function, supporting our hypothesis that glucose control in the post-QIP cohort was too narrow to show the effect of hyperglycemia on terminal renal function.
We then assessed renal graft function in the corresponding recipients by examining rates of delayed graft function. An accumulating body of evidence indicates that DGF in kidney recipients increases rates of acute rejection, reduces graft and patient survival, and increases health care costs. [8] [9] [10] [11] [12] [13] [14] [15] 18, 38, 39 DGF is a universally captured end point and also consistently documented in the UNOS database.
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We assessed the occurrence of DGF in kidney recipients matched to donors in this study. We did not demonstrate a highly significant direct correlation between donor glucose control and DGF in recipients. In the first portion of the study, we demonstrated a strong correlation between donor hyperglycemia and donor terminal renal function by using combined data from both cohorts. Given the existence of risk prediction models identifying terminal creatinine level as one of the most significant risk factors for DGF, we would expect to find associations between hyperglycemia in deceased organ donors and DGF in matched recipients. 16, 17 Several factors may contribute to the observed results. The study may be underpowered to detect an association between donor glucose control and recipient DGF. The threshold for initiating dialysis on postoperative kidney transplant recipients may have also changed with evolving clinical practice and most likely varies between providers and institutions. Another important factor is the presence of additional recipient variables that affect the occurrence of DGF. 14, [16] [17] [18] 38, 39 These recipient variables may obscure correlations between donor variables, such as glucose homeostasis, and DGF.
Assessing the effects that a donor management intervention has on the recipients of the corresponding organs is difficult for multiple reasons. For example, managing data from multiple relational databases is challenging. Also, when the predictor variable is being measured in one population (the donors) and the outcome of interest is being measured in a separate heterogeneous population (the recipients) with its own set of interacting variables, it becomes very difficult to control for all interactions and to identify independent correlations.
Despite these barriers to donor-recipient research, we made an indirect correlation between glucose control in deceased donors and DGF in recipients. We first demonstrated that mean glucose concentration during the period between declaration of brain death and organ recovery is an independent predictor of terminal renal function. We then went on to show that terminal renal function in the same set of donors is an independent predictor of DGF in the matched kidney recipients. Evidence is accumulating that terminal creatinine level in deceased donors is a strong predictor of DGF in kidney recipients. Therefore, a donor management strategy that can improve terminal renal function (organ quality) may ultimately improve outcomes in the recipients of those kidneys.
The study has several strengths and limitations. One of the strengths is that by combining donors from both the pre-QIP cohort and the post-QIP cohort, we have a large donor cohort from a single OPO that uses a common protocol. Another strength is that the 2 donor cohorts were demographically fairly similar, which is important when assessing the effect of an intervention in a retrospective manner.
One significant limitation of the study is that the data were not collected in a randomized or prospective manner, leading to many confounding relationships. Confounding interactions are particularly problematic when assessing for a relationship between glucose control in donors and DGF in recipients. However, our multivariate models suggest that the effect of donor glucose concentration on terminal renal function and the effect of terminal renal function on recipient DGF are not related to other more significant variables.
These results suggest that aggressive management of hyperglycemia in deceased donors is a donor management strategy with the potential to improve the quality of donor kidneys and the outcomes of transplanted renal allografts. In order to address the limitations of a retrospective study design and more rigorously examine the effects of donor glucose control and recipient outcomes, the next step would be to conduct a prospective randomized study evaluating the effects of intensive insulin therapy on renal function in deceased donors. Such a study will hopefully validate the benefits of aggressive glucose management in deceased donors.
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